Menzag skin ointment 0.05% Medboide reduces inflammation and itching of dermatology

Dosage form Box
Specifications Diflorasone diacetat

Ingredient

Composition information	Content
Diflorasone diacetat	0.05%

Uses

indicators

Menzag skin ointment is a product containing the active ingredient Diflorason diacetate 0.05% W/W belongs to the corticosteroid group, the sugar is used on the spot. The drug is used to reduce inflammation and itching of dermatological disease that responds to corticosteroids in adults.

Pharmacokology

ATC code: D07AC10

local sugar corticosteroids have anti -inflammatory, anti -itching and vasoconstriction effects. The mechanism of anti -inflammatory activity of corticosteroid sugar is not clear. Different testing methods, including quantification of the vasoconstrictor effect of the drug, are also used to compare and predict the potential and/or clinical effects of corticosteroids in place. There are some evidence that suggests an easy -to -identifying correlation between the potential of the vascular effect of the drug and the effectiveness of human treatment.

Dynamic pharmacokinetics

The level of skin absorption of corticosteroids on the spot is determined by many factors, including skin transportation, skin integrity and treatment of treated skin. Located sugar corticosteroids can be absorbed from the normal intact skin. Inflammation and/or other skin diseases increase the absorption through the skin. The bandage significantly increases the skin absorption of corticosteroids in place. Therefore, the bandage can be a valuable therapy to treat anti -drug dermatological diseases. When absorbed through the skin, corticosteroids are locally used with pharmacokinetic characteristics similar to that of sugar corticosteroids. Corticosteroids linked to plasma proteins at different levels. They are metabolized mainly in the liver and then excreted by the kidneys. Some of the sugar corticosteroids are locally used and their metabolites are also eliminated through the bile.

Before taking Menzag skin ointment 0.05% Medboide reduces inflammation and itching of dermatology

How to use

Menzag skin ointment is only used on the spot. Avoid contact with eyes.

Dosage

Apply a thin layer to the treated skin, 1-3 times/day depending on the severity and anti -drug quality of the province.

Wash your hands after each drug.

Non -covered skin treatment unless prescribed by a treating doctor.

If infected, remove the iron on the skin and use the appropriate antifungal/antibiotic.

Treatment time: Applying the drug within 2 weeks and assessing the condition of the drug -based response based on improving inflammation, can last for 2-3 weeks depending on the doctor's instructions.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose?

How to handle overdose: Actively monitor for timely treatment.

What to do when forgetting 1 dose?

Side Effects

The following unwanted effects have been determined from clinical trials or from field surveys. Due to these unwanted effects reported from the common population of unknown sample size, it is not always estimated to be frequency as well as building causal relationships with the exposure of corticosteroids in place.

Unwanted effects may occur more often when using localized corticosteroids when there is a bandage in the skin treatment or used for a long time.

Skin and subcutaneous tissue: Burns, itching, irritation, dryness, folliculitis, hairy, acne, hypogy, dermatitis around the mouth, dermatitis due to allergies, skin peeling, secondary infections, skin atrophy, stretch marks and heat rash.

Eye: cataract, glaucom, retinal retinal center (CSCR: Central Serous Chorioretinopathy).

Notify the doctor with unwanted effects when using the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Menzag skin ointment is contraindicated in the following cases:

Patients with a history of hypersensitivity to any component of the drug.

Caution when using

Warning

Local -spot corticosteroid corticosteroids (including menzag) may increase the risk of cataracts and glaucom. There has been a report on cataract from the actual use of Diflorason diacetat preparations on the spot. There has been a report on Glaomom (at risk of visual nerve damage) and increasing the inner pressure from the actual use of local corticosteroids for dermatological diseases. Avoid giving Menzag in contact with the eyes. Advise patients to report to the doctor if there is any eye symptoms.

Precautions

Body

The whole body absorption of local sugar corticosteroids used inhibitors has a hypothalamus restoration - pituitary - adrenal gland, manifestation of cushing syndrome, hyperglycemia and urinary glucose in some patients.

Conditions to increase the body's body absorption of corticosteroids in place including steroid overdose, applying drugs on the skin surface area that is too wide, used for a long time and with bandages.

Therefore, patients taking high doses of steroids on the spot on the wide or bandaged skin area should be periodically evaluated for evidence of hypothalamus inhibitors - pituitary - adrenal glands by testing the stimulation of ACTH and cortisoluria. If the axial inhibition occurs, the pituitary - adrenal gland, should stop steroids, reduce the frequency of steroids or use a lower potential steroid.

Hill -shaft function - pituitary - adrenal glands often recover quickly and completely after stopping the drug. There are few signs and manifestations of steroid stops that cause patients to use systemic corticosteroids.

Children may have a higher ratio of corticosteroid absorption and therefore more likely to experience systemic toxicity.

If irritated, corticosteroids should be used in place and use appropriate therapy.

If there is a symptom of skin infection, an antifungal or an antibiotic should be used. If there is no timely response, corticosteroid should be stopped until the infection is controlled.

Information for patients

Patients using corticosteroids should know the following information:

This drug is only used under the prescription of a doctor, only used on the skin, avoiding eye contact.

Patients should not take this medication for any other condition.

notify the doctor if the patient has a blurred vision or visual disorder.

Do not bandage or seal the skin is treated unless prescribed by a doctor.

Patients should report to the doctor about any signs of unwanted effects, especially when bandaged or sealed with treatment.

Pediatric parents should not be used for tight cholera or plastic pants when treating the diaper wrapped skin because it can clog.

Testing

The following tests can be helpful in assessing the inhibition of hypothalamus - pituitary - adrenal glands: Cortisol tests, ACTH stimulation tests.

Cancer, gene mutations and fertility reduction

There are no long -term studies on animals to assess the risk of cancer or affect the fertility of corticosteroids in place.

diflorason diacetat does not cause gene mutations in a micro -micro -test test in the culverts with peritoneal doses of up to 200 mg/kg.

Children

Safety and effectiveness of Diflorason diacetat ointment in children has not been evaluated. Due to the higher skin surface ratio than the body mass, children are at higher risk of being inhibited the hypothalamus - pituitary - adrenal gland when using local corticosteroids. Therefore, these patients are also at higher risk of glucocorticosteroid deficiency after stopping treatment and cushing syndrome during treatment. There have been reports on unwanted effects of stretch marks when using corticosteroids in place not suitable in children.

There have been reports on the inhibition of hypothalamus - pituitary - adrenal glands, intraocular hypertrophic cushing syndrome in children using topical corticosteroids. Manifestations of adrenal inhibition in children include underdeveloped retardation, slow weight gain, low plasma cortisol levels and no ACTH stimulation response. Manifestations of internal turbocharger include fontanel, headache and thorns on both sides.

Elderly

Clinical studies of Diflorason Diacetat Diu Type Topic in place are not conducted in patients ≥ 65 years old to determine the difference in response between them and younger patients.

The effect of the drug on driving and operating machinery

There is no evidence of the effect of the drug on the ability to drive and operate machinery.

Using drugs for women during pregnancy and lactation

Using drugs for pregnant women

In animals, corticosteroids do not cause teratogenicity when using low -dose systems. For corticosteroids with stronger potential, there is a monster after using skin drugs in experimental animals. There are no appropriate control studies in pregnant women about the teratogenic effect of local corticosteroids. Therefore, corticosteroids should not be used in place during pregnancy when the treatment benefits are considered to be higher than the risk that may occur in the fetus. The drugs of this group should not be widely used for pregnant women in large doses or for a long time.

Using medicine for breastfeeding women

It is not known whether the corticosteroid is locally used, causing a full amount of body absorption to be able to quantify in breast milk or not. Because many drugs are secreted into breast milk, caution should be cautious when taking this medication for breastfeeding women.

Interactive drug

Interaction of drugs

No information.

Tyeum of drugs

Due to the absence of studies on the correlation of the drug, not mixing this drug with other drugs.

Storage

In a dry place, avoid light, the temperature does not exceed 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.